Robuta

https://www.nature.com/articles/s41467-025-60884-1?error=cookies_not_supported&code=cd882ef6-bfda-43ae-a35e-0edb9b8944f8 JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms... Jul 8, 2025 - JAK (Janus Kinase) inhibitors, such as ruxolitinib, were introduced a decade ago for treatment of myeloproliferative neoplasms (MPN). To evaluate ruxolitinib’s... myeloproliferative neoplasmsselectionraspathwaymutations https://www.cancerresearchuk.org/about-cancer/myeloproliferative-neoplasms Myeloproliferative neoplasms | Cancer Research UK Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells. cancer research ukmyeloproliferative neoplasms